Today at ViVE 2024, CancerX announced the 16 startup members of its inaugural Accelerator cohort, launched in partnership with MassChallenge: The Blue Box, C the Signs, Cancer Insights, Curvia, EnteroTrack, Gesund.ai, Gray Oncology, Lind AI, Mika Health, Navya, Oatmeal Health, Orbit Genomics, Realyze Intelligence, Reimagine Care, SurvivorPlan and Xanthos.
These digital innovators were selected from a strong pool of applicants after three rounds of judging led by Accelerator Champions Debiopharm, Reveal HealthTech, UCDavis Health, Atrium, Dell Technologies, Intel, AstraZeneca, AWS and Oncology Ventures, as well as judges from the CancerX community. The inaugural cohort proposed ideas to reduce the burden of cancer for all people focused on using digital innovation in the areas of clinical research; screening and diagnosis; treatment and management; clinical operations; and patient, caregiver and survivor experience.
Launched one year ago, CancerX, a public-private partnership announced by the White House as a national accelerator to boost innovation in the fight against cancer, and its more than 150 members are working to achieve the national goals for the Cancer Moonshot of reducing the death rate from cancer by at least 50% over the next 25 years and improving the experience of people and their families living with and surviving cancer.
Full story: CancerX Announces Inaugural Start-Up Accelerator Cohort | Moffitt
